, hubei daily newspaper reported on June 20th, happy people have joint fund Yangtze river and han medicine capital to complete the subdivision of the pharmaceutical industry leading RiteDose company acquisitions, the introduction of BFS (bottle, filling and sealing) technology in hubei province.
The acquisition, which involved $605 million in funding, rerefreshed the amount of the company's acquisitions.
$605 million fund, 70% come from abroad, by the Yangtze river industrial fund joint handler, capital was established in August of last year's $1 billion han DE industrial 4.0 industry to promote cross-border fund is responsible for the management. And human blessing medicine will undertake BFS core technology project to be born hubei.
Pay big money to buy RiteDose company was founded in 1995, in the United States BFS technical production of a single dose of sterile products niche ranked first, sterile pharmaceutical annual output more than 1.7 billion cigarettes, mainly used for the treatment of respiratory and eye disease, annual sales of $150 million, sterile drug annual output of more than 1.7 billion hits.
The biggest bright spot for the merger is the exclusive use of the world's most advanced BFS technology and a gap in the country's vital technology. After the purchase, the company will invest 500 million yuan to build the first mature BFS plant in China, which covers an area of about 100 acres, and is expected to generate $500 million in global sales by 2020.
China's BFS technology lags behind, and over 90% of the pharmaceutical products need to be imported, and the market is monopolized by foreign enterprises. The introduction of BFS technology can greatly promote the research and development of domestic drugs, improve drug quality, and reduce dependence on imported drugs. According to the person in charge of human fu medicine, this technology will combine with people's existing narcotic drugs, API, and further enhance the added value of drugs. Take the case of the ge store factory, one of which is the production of raw materials for budesonide (drugs) and BFS technology, which directly produces the drug.
At this point, the international pace of human blessing medicine has been accelerating comprehensively, and has gradually grown into a multinational pharmaceutical company based in wuhan.
Overseas expansion accelerates
In just one year, the pace of human blessing medicine has entered the outbreak period. Since last may, three us drug companies have been acquired for one year.
In May 2016, the us pharmaceutical company Pharma and RE Holdco were included in the us $550 million by the us pharmaceutical company Pharma and RE Holdco. On May 26, 2017, happy people to Australia 4.1 billion yuan price gloves and surgical masks manufacturers Ansell condoms and lubricants business, involving business including the kappa brand named after agent James Bond.
As a matter of fact, the medicine in the United States from the end of 2015 the joint venture company of the United States received FDA poke about hydrochloric acid dollars just piece approval number, gradually to profit, people f pharmaceutical market in the United States had push to early cultivation. Prior to this, people's overseas development business has been laid out for more than eight years. As early as 2008, the company formed a joint venture with the us company ENSPIRE to build a foundation for its own products, using its familiarity with U.S. policy requirements and market conditions. In 2011, the company raised $15.08 million to the us, and its stake rose to 77 per cent.
Since then, people blessing side USES the means of capital acquisition ANDA approval document, set up wholly owned people f poke (wuhan) co., LTD., take advantage of the Chinese market Labour costs and API, to the United States and the European mainstream market output soft capsule products and health products, etc. Puck is also helping to get a quick FDA approval.
In 2015, the overseas market revenue of the company was 447 million yuan, up by 80.23% year on year. Subsequently, a $550 million purchase of a big single acquisition, which not only has a rich pipeline of research and development, but also the marketing network, business philosophy and so on, can also help the global marketing network. This also marks the stage in which the export strategy of the pharmaceutical preparation for pharmaceutical preparation is directed to direct export and the merger of capital and acquisition.
The annual revenue of overseas regions reached 1.06 billion yuan in 2016, a year-on-year increase of 136.40 percent, according to the annual report. Gross margin compared to last year increased by 1.27%, but is still in a lower level, therefore, of the overseas market through low cost low price strategy is not a long-term solution, people f medicine must be enough competitive products to expand overseas markets, and by means of capital m&a is definitely the quickest.
"To be a real multinational, you have to have the technology, the brand and the marketing channel of globalization," says the head of the company. This time, the price paid a lot of money to buy BFS technology, on the one hand, greatly improve the international competitiveness of the product, on the one hand acceleration internationalization layout and the next city.
At the same time, critics say, in the process of acquisition of ji on with citic capital buyout funds to participate in, the offer shall be the responsibility of the industrial capital funds, f medicine is responsible for the overall operation, shows the layout approved by capital in overseas markets.
2. Buy and sell
Buy, sell. On June 12, people f medicine for about 2.4 billion yuan price will be its wholly owned subsidiary of wuhan zhongyuan rhett biological products co., LTD. 80% stake in the transfer to the world's largest blood product company CSL Limited a wholly owned subsidiary of jetter belin (Asia Pacific) co., LTD.
According to the people's medical bulletin, zhongyuan reed relies on the growth of endogenous growth to realize the scale effect, which is subject to many restrictions, and the industry leading enterprises are facing many challenges. To sell a 80% stake in zhongyuan rhett will bring to the company investment about 2.1 billion yuan, is advantageous to the company to reduce the asset-liability ratio, focus on niche that have competitive edge, jet belin advanced international technology can also improve the company enjoyed by zhongyuan rhett the value of the remaining 20% stake.
Blood products manufacturing enterprises in China is small, the product of a single, industry concentration is not high, and the status quo of cannot be self-sufficient, stressed that adhere to the "do medicine health niche market leader" of the medicine out of the competitive advantage is not obvious or synergies weaker areas of blood products is let nature take its course. And compared with its core drug business, the company's net profit did not stand out in the company's overall performance.
In addition to spinning off non-core businesses and enhancing the competitiveness of core products, the $2.1 billion sale of centaline is also seen as a "quenching thirst" for corporate indebtedness. In recent years, in the process of transition to internationalized drug companies, the asset-liability ratio of people's medicine has risen rapidly, reaching 49.42% in 2015, higher than the industry average, and rising to 54.66% in 2016. On September 1, 2016, the company announced a plan to raise $2.8 billion to "supplement blood".
A voice says, people f the biggest competitive advantage is still the ganga drugs, in the future should be use for many years the brand competitiveness in new drug research and development, the focus of the current business layout of happy people too scattered, such as herbal tea, do sexual health supplies, etc. In the strategic planning for 2017, we will also include the development of the sub-center of the moon, the maintenance of traditional Chinese medicine, the rehabilitation of the elderly, assisted reproduction and other light asset derivatives. When it came to the acquisition of jasper, there were also voices questioning the move by wang xuehai, the head of the pharma group, as a "emotional case" that was not in line with the plan to "divest non-core businesses and accelerate the layout of the us market".
In fact, in the process of buying and selling, people's medicine has gradually built its core advantages. In 2016, the revenue of the product line of the family of fu medicine was down 6.28% from 2015, so the addition of condom business can be regarded as enhancing the business capacity of this field. The acquisition of RiteDose, a us medical-subdivision, is also a key part of its 2017 plan to "improve the profitability of international businesses". (Yang xinyuan) |
